<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882021</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10275</org_study_id>
    <nct_id>NCT03882021</nct_id>
  </id_info>
  <brief_title>High-Density (HD) Wave Mapping in Subjects With Atrial Fibrillation as a Predictor of Recurrence After a Single Ablation Procedure Using a PVI-Only Strategy</brief_title>
  <acronym>WAVE-MAP AF</acronym>
  <official_title>High-Density (HD) Wave Mapping in Subjects With Atrial Fibrillation as a Predictor of Recurrence After a Single Ablation Procedure Using a PVI-Only Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to use the GRID to characterize the atrial substrate and develop a model for
      predicting recurrence rates after a single procedure using a PVI only approach and a contact
      catheter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical investigation is intended to characterize the left atrial substrate using the
      Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ in an HD Wave configuration and correlate
      different factors with 12-month success after a single ablation procedure using a pulmonary
      vein isolation (PVI) approach without further substrate modification.

      This is a post-market, single-arm, multi-center, prospective interventional study of the
      Advisor™ HD Grid Mapping Catheter, Sensor Enabled™. This study is aimed at determining
      correlations between pre-ablation mapping characteristics and outcomes after catheter
      ablation of atrial fibrillation.

      Approximately 300 subjects at up to 20 sites worldwide will be enrolled.

      Subjects will be followed until they complete their 12-month visit. Clinical Investigation
      visits will occur at Baseline (confirmation of eligibility), Index Procedure, 3 months, 6
      months, and 12 months. Endpoints will be analyzed when all subjects have completed their
      12-month follow up visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects enrolled will undergo the same mapping and ablation protocol.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One-year success</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as freedom from atrial fibrillation, atrial flutter and atrial tachycardia after removal from the antiarrhythmic drug therapy as assesses from the end of the 3-month blanking period to 12 months following a single ablation procedure. Survival analysis will be conducted to analyze time-to-event variables.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Acute procedural success</measure>
    <time_frame>During procedure</time_frame>
    <description>Defined as electrical isolation of all pulmonary veins. The data will be summarized with subject counts and percentages/rates, and with exact 95% Clopper-Pearson confidence intervals.</description>
  </other_outcome>
  <other_outcome>
    <measure>Success post blanking period through 12 months using different definitions</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from symptomatic AF/AFL/AT after removal from antiarrhythmic drug therapy
Single procedure clinical success defined as freedom from symptomatic atrial fibrillation, atrial flutter and atrial tachycardia without a new or increased dose of class I or III antiarrhythmic drug
Freedom from atrial fibrillation, atrial flutter and atrial tachycardia Survival analysis will be conducted to analyze time-to-event variables.</description>
  </other_outcome>
  <other_outcome>
    <measure>Arrhythmia recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Rates of recurrence not due to PVI gap for subjects with repeat electrophysiology studies. The data will be summarized with subject counts and percentages/rates, and with exact 95% Clopper-Pearson confidence intervals.</description>
  </other_outcome>
  <other_outcome>
    <measure>Left atrium (LA) information</measure>
    <time_frame>During procedure</time_frame>
    <description>LA volume will be summarized with the numbers of observations, means with standard deviations, quartiles, minimums, maximums and 95%confidence intervals for the means.</description>
  </other_outcome>
  <other_outcome>
    <measure>Left atrium information</measure>
    <time_frame>During procedure</time_frame>
    <description>LA diameter will be summarized with the numbers of observations, means with standard deviations, quartiles, minimums, maximums and 95%confidence intervals for the means.</description>
  </other_outcome>
  <other_outcome>
    <measure>Reportable Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>including any device-, procedure-, or death-related events. The data will be summarized with subject counts and percentages/rates, and with exact 95% Clopper-Pearson confidence intervals.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <condition>Persistent Atrial Fibrillation</condition>
  <condition>Cardiac Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Mapping protocol with GRID catheter</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patient will undergo a protocol required mapping protocol using the GRID catheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>A specific electrophysiology mapping protocol is applicable with the GRID catheter.</intervention_name>
    <description>The procedure will be done according to a standard ablation approach. During the electrophysiology study, additional mapping data will be collected to support the study endpoints using the GRID catheter.</description>
    <arm_group_label>Mapping protocol with GRID catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented atrial fibrillation with planned endocardial ablation procedure

          2. Age 18 years or older

          3. Able and willing to provide written informed consent prior to any clinical
             investigation related procedure

          4. Able and willing to complete all required study procedures through 12 months

        Exclusion Criteria:

          1. Long-standing persistent atrial fibrillation defined as continuous AF greater than 12
             months in duration

          2. Previous ablation or surgery in the left atria

          3. Implanted left atrial appendage occluder

          4. Implanted mitral or tricuspid valve replacement

          5. Implanted cardiac defibrillator (ICD)

          6. Participation in another clinical investigation that may confound the results of this
             study

          7. Pregnant or nursing

          8. Presence of other anatomic or comorbid conditions, or other medical, social, or
             psychological conditions that, in the investigator's opinion, could limit the
             subject's ability to participate in the clinical investigation or to comply with
             follow-up requirements, or impact the scientific soundness of the clinical
             investigation results.

          9. Life expectancy less than 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin Ruffner</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krista Hicks</last_name>
    <phone>+1-859-816-1567</phone>
    <email>krista.hicks@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karolien Timmermans</last_name>
    <phone>+32497513921</phone>
    <email>karolien.timmermans@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum GmbH</name>
      <address>
        <city>Linz</city>
        <state>Upr Aus</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Steinwender, MD, Prim.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>FN U sv. Anny v Brno</name>
      <address>
        <city>Brno</city>
        <state>Moravia-Silesia</state>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zdenek Starek, MD, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR de La Reunion - Site du CHFG</name>
      <address>
        <city>Saint-Denis Cedex</city>
        <state>ILE</state>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gael CLERICI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé du Confluent</name>
      <address>
        <city>Nantes</city>
        <state>Paysdel</state>
        <zip>44200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Gras, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Médipôle Lyon-Villeurbanne</name>
      <address>
        <city>Villeurbanne</city>
        <state>Rhone</state>
        <zip>69626</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herve Poty, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ingolstadt GmbH</name>
      <address>
        <city>Ingolstadt</city>
        <state>Bavaria</state>
        <zip>85049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karlheinz Seidl, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz- u. Gefäßzentrum Bad Bevensen</name>
      <address>
        <city>Bad Bevensen</city>
        <state>L Saxon</state>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny Lyan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Sommer, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombard</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Della Bella, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <state>Tuscany</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Grazia Bongiorni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medische Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuri Blaauw, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Cruz</name>
      <address>
        <city>Carnaxide</city>
        <state>Lisbon</state>
        <zip>2799-523</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Adragao, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Martinez Sande, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Rivas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Betts</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

